MSKCC relies on the counsel of outside advisors, represented by its Board of Scientific Consultants (BSC), the guidance of its Board of Overseers and Managers, as well as many internal planning processes to support the planning and evaluation of the research programs and core facilities at the Center. MSKCC has used the guidance it has received to develop and execute its initiatives for research and clinical expansion. During the past five years, the BSC has reviewed the research in many areas, including the Developmental and Stem Cell Biology Program, the Molecular Structure Program, the Prevention, Control and Population Research Program (now the Survivorship, Outcomes, and Risk Program), along with its efforts in Immigrant Health and Cancer Disparities, the Immunology and Transplantation Program, the Imaging and Radiation Sciences Program, the Cancer Biology and Experimental Pathology Program, Experimental Therapeutics, and disease-specific components of the Clinical Research Program. The BSC has also reviewed some of the newly recruited junior investigators and the training programs that bring outstanding students to train in MSKCC's laboratories. In addition to the BSC, the senior leaders receive strategic counsel from the MSKCC Board of Overseers and Managers to provide both community and financial stewardship as well as tactical advice on Center policies. A Task Force was also created to internally evaluate the Cores' infrastructure, and several improvements have been enacted. Through input from program members and the Associate Directors, further collaborative research centers that foster interactions between laboratory and clinical investigators have also been established. The recommendations made by the BSC and other planning groups have led to program reorganizations, new faculty recruitments, shared resource development, and facility expansions.

Public Health Relevance

MSKCC's planning and evaluation processes provide external and internal counsel for its research programs. The expert advice that it receives guides the development of its strategic initiatives so that it can best meet the mission of an NCI-designated Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-52S1
Application #
9624053
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
52
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Schlappe, Brooke A; Weaver, Amy L; Ducie, Jennifer A et al. (2018) Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. Gynecol Oncol 151:235-242
Pareja, Fresia; Da Cruz Paula, Arnaud; Murray, Melissa P et al. (2018) Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. J Clin Pathol :
Yao, Zhan; Gao, Yijun; Su, Wenjing et al. (2018) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med :
Dumane, Vishruta A; Saksornchai, Kitwadee; Zhou, Ying et al. (2018) Reduction in low-dose to normal tissue with the addition of deep inspiration breath hold (DIBH) to volumetric modulated arc therapy (VMAT) in breast cancer patients with implant reconstruction receiving regional nodal irradiation. Radiat Oncol 13:187
Turashvili, Gulisa; Fix, Daniel J; Soslow, Robert A et al. (2018) Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases. Int J Gynecol Pathol :
Krantz, Benjamin A; O'Reilly, Eileen M (2018) Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality? Clin Cancer Res 24:2241-2250
Chowell, Diego; Morris, Luc G T; Grigg, Claud M et al. (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359:582-587
Morgani, Sophie M; Metzger, Jakob J; Nichols, Jennifer et al. (2018) Micropattern differentiation of mouse pluripotent stem cells recapitulates embryo regionalized cell fate patterning. Elife 7:
Senders, Max L; Que, Xuchu; Cho, Young Seok et al. (2018) PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis. J Am Coll Cardiol 71:321-335
Fang, Jing; Muto, Tomoya; Kleppe, Maria et al. (2018) TRAF6 Mediates Basal Activation of NF-?B Necessary for Hematopoietic Stem Cell Homeostasis. Cell Rep 22:1250-1262

Showing the most recent 10 out of 8799 publications